Application of RBMS1 knocking-down reagent in preparation of medicine for treating triple negative breast cancer

A triple-negative breast cancer and drug technology, applied in the field of anti-tumor drugs, can solve the problems of lack of effective target molecules, inability to stimulate anti-cancer immunity, lack of triple-negative breast cancer, etc., and achieve the effect of enhancing sensitivity

Active Publication Date: 2022-03-18
DALIAN MEDICAL UNIVERSITY
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Triple-negative breast cancer is one of the molecular types of breast tumors. Since estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (Her2) are all negatively expressed, there has been no effective treatment. Targeting molecules as a therapeutic strategy, and most triple-negative breast cancer patients show limited response to immunotherapy, especially when tumors lack tumor-infiltrating lymphocytes to stimulate anticancer immunity
However, potential target molecules for combination cancer immunotherapy against triple-negative breast cancer are currently lacking

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of RBMS1 knocking-down reagent in preparation of medicine for treating triple negative breast cancer
  • Application of RBMS1 knocking-down reagent in preparation of medicine for treating triple negative breast cancer
  • Application of RBMS1 knocking-down reagent in preparation of medicine for treating triple negative breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0215] RBMS1 regulates PD-L1 expression in triple-negative breast cancer cells

[0216] The results of immunohistochemical staining of cancer tissues and normal breast tissues in breast cancer patient tissues showed that the expressions of RBMS1 and PD-L1 in triple-negative breast cancer tissues were higher than those in normal tissues and Her2-positive breast cancer tissues ( figure 1 In A), the expression intensity analysis of the two in different types of breast cancer, the results are as follows figure 1 As shown in B in the figure: both PD-L1 and RBMS1 are highly positive in triple-negative breast cancer (TNBC), which also reveals that RBMS1 and PD-L1 are highly expressed in most tissues of patients with triple-negative breast cancer.

[0217] figure 1 The expression of RBMS1 and PD-L1 in breast cancer patients; where, A: the expression of RBMS1 and PD-L1 was detected by immunohistochemical staining in breast cancer patients and normal breast tissues, B: breast cancer wi...

Embodiment 2

[0221] RBMS1 regulates tumor cell anti-immunogenicity and inhibits tumor growth

[0222] The established control sh and RBMS1 sh stably transformed cell lines in 4T1 cells were subcutaneously inoculated in immunocompetent Balb / c mice, and the tumor growth of the mice after tumor bearing was observed. The tumor size of the mice in the RBMS1sh group was significantly smaller than that in the control sh group. See image 3 In (A-C), the levels of interferon-γ (IFN-γ) and granzyme B (GzmB) secreted by T cells in lymph nodes, spleen and tumor were analyzed, the results showed that CD8 in RBMS1 sh group + The cells secreted gamma interferon (IFN-γ) and granzyme B (GzmB) were significantly higher than those in the control sh group, see image 3 Middle D and E.

[0223] image 3 Knockdown of RBMS1 can enhance the anti-immunogenicity of tumor cells; among them, A-C: 5-week-old female Balb / c mice were subcutaneously inoculated with 200,000 cells / mouse, and the tumor size of the mice ...

Embodiment 3

[0225] RBMS1 regulates its transcription by binding to the 3'-UTR of the glycosyltransferase B4GALT1

[0226] In order to further explore the regulation of RBMS1 and mechanistically study how RBMS1 down-regulates the expression of PD-L1, the present invention performed RNA-seq assay on RBMS1 knockdown cells in MDA-MB-231. The present invention finds that glycosyltransferase β-1,4-galactosyltransferase 1 (B4GALT1) is one of the most important proteins, and then the present invention verifies its protein level and mRNA level at the cellular level, such as Figure 4 Shown in A. B4GALT1 mRNA levels were significantly decreased after knockdown of RBMS1, Figure 4 B4GALT1 protein level was also significantly decreased after knockdown of RBMS1 in B. In order to further explore the mechanism of its regulation of B4GALT1 expression, an experiment to detect its RNA stability was carried out, such as Figure 4 In C, after adding actinomycin D to the cells for 0, 4, 8, and 12 hours, th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of a reagent for knocking down RBMS1 in preparation of a medicine for treating triple negative breast cancer, and belongs to the technical field of anti-tumor medicines. The invention provides application of a reagent for knocking down RBMS1 in preparation of a medicine for treating triple negative breast cancer. The knock-down of the RBMS1 gene in the triple negative breast cancer can inhibit B4GALT1 gene transcription and then down-regulate PD-L1 expression so as to influence the ability of infiltrating lymphocytes in tumors to kill tumor cells, enhance the sensitivity of triple negative breast cancer immunotherapy and provide a new potential target for triple negative breast cancer immunotyping and treatment.

Description

technical field [0001] The invention relates to the technical field of anti-tumor drugs, in particular to the application of a reagent for knocking down RBMS1 in the preparation of a drug for treating triple-negative breast cancer. Background technique [0002] Triple-negative breast cancer is one of the molecular types of breast tumors. Since estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (Her2) are all negatively expressed, there has been no effective treatment. Targeting molecules as a therapeutic strategy, and most triple-negative breast cancer patients show limited response to immunotherapy, especially when tumors lack tumor-infiltrating lymphocytes to stimulate anticancer immunity. Therefore, identifying suitable targets that can enhance the immunogenicity of TNBC will provide a new approach to improve immunotherapy against TNBC. Programmed death ligand-1 (PD-L1; also known as B7-H1 or CD274) is a 33kDa type I transmembrane p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K45/06A61K39/395A61P35/00C12Q1/6886
CPCA61K45/00A61K45/06A61K39/3955A61P35/00C12Q1/6886C12Q2600/158C12Q2600/112A61K2300/00Y02A50/30
Inventor 汪洋张金瑞张鸽张文静祁旸凡赵瑾瑶白璐李田田王鹿宁
Owner DALIAN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap